Novartis' Entresto Blockbuster Status On Track After CHMP Backing
This article was originally published in Scrip
Novartis' heart failure pill Entresto is already predicted to reach blockbuster status on the strength of its July approval in the US and now formal recommendation by CHMP in Europe for patients with reduced ejection fraction – representing some 50% of chronic heart failure patients - but those prospects could soar if an ongoing Phase III study presents the opportunity to eventually move the agent into the other half of chronic heart failure patients, those having preserved ejection fraction.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.